Clinical trials: FL
Oral Squamous Cell Carcinoma (OSCC)
A Dye for the Detection of Cancer of the Tongue and Mouth
The purpose of this study is to test if an investigational dye, called PARPi-FL, can be used to detect this type of cancer. This will be the first time that PARPi-FL is being tried in people.
- Trial name
- NCT03085147
- Testing
- Olaparib
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Marginal Zone Lymphoma, Follicular Lymphoma
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
This was a multicenter, open-label, phase 2 study to evaluate efficacy, safety, and tolerability of BGB-3111 (zanubrutinib) 160 milligrams (mg) twice daily (BID) in combination with rituximab in Chinese participants with…
- Conditions
- Marginal Zone Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03520920
- Testing
- Zanubrutinib, Rituximab
- Where
- 4 sites in China
- Volunteers
- 41 people
- Sponsor
- BeiGene
DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
To evaluate the efficacy and adverse effects of lenalidomide combined with G-CHOP(LO-CHOP) in the treatment of newly diagnosed diffuse large B-cell lymphoma with follicular lymphoma (CDLBCL-FL).
- Trial name
- NCT06151080
- Testing
- Lenalidomide combined with G-CHOP (LO CHOP)
- Where
- China
- Volunteers
- 38 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Follicular Lymphoma (FL)
Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma
This Phase II, multi-center, single-arm, open-label study evaluates the efficacy and safety of TC011, a CD19-targeted CAR-T cell therapy, in adult patients with relapsed or refractory follicular lymphoma (Grade 1, 2, or 3a).
- Trial name
- TC011_FL_201 (NCT07360288)
- Testing
- TC011 single-arm
- Volunteers
- 40 people
- Sponsor
- TICAROS Co., Ltd.
Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL)
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
This study is designed as a long-term follow-up study of participants who have receive genetically modified autologous CLBR001 CAR-T cells
- Conditions
- Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT04488354
- Testing
- CLBR001 and SWI019
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Calibr, a division of Scripps Research
Pancreas Cancer
Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.
To determine recommended phase 2 dose and to evaluate the safety of vactosertib in combination with nal-IRI/FL in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who have failed first-line gemcitabine and…
- Trial name
- NCT04258072
- Testing
- Vactosertib
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Samsung Medical Center
Follicular Lymphoma
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
This study aims to observe and explore the efficacy and safety of obinutuzumab-based therapy for previously untreated follicular lymphoma
- Trial name
- NCT05899621
- Testing
- Obinutuzumab, Lenalidomide, Bendamustine
- Where
- China
- Volunteers
- 332 people
- Sponsor
- Ruijin Hospital
Follicular Lymphoma
A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
This study focuses on finding a safe and tolerable dose for a three-drug regimen that combines venetoclax (Venclexta Ⓡ), CC-486 (also known as oral azacitidine) and obinutuzumab (Gazyva Ⓡ) to treat cancer participants who have…
- Trial name
- NCT04722601
- Testing
- Venetoclax, Obinutuzumab, CC-486
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Chicago
Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
This Phase Ib/II, open-label, multicenter, non-randomized study will evaluate the safety, efficacy, and pharmacokinetics of induction treatment consisting of atezolizumab in combination with either obinutuzumab + bendamustine…
- Trial name
- NCT02596971
- Testing
- Atezolizumab, Bendamustine, Cyclophosphamide
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 91 people
- Sponsor
- Hoffmann-La Roche
Periodontitis
Effectiveness of Adjunctive Therapy of Emdogain®FL in Non-surgical Periodontal Treatment
The goal of this clinical trial is to assess the safety and effectiveness of adjunctive Emdogain® therapy in non-surgical periodontal treatment for patients with stage 3 and 4 periodontitis.
- Trial name
- NCT06070181
- Testing
- Enamel matrix derivate, Non-surgical periodontal treatment
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Ostergotland County Council, Sweden
Relapsed Follicular Lymphoma
A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)
This is a Phase III, multicenter, open-label, randomized and controlled study to compare the efficacy of a consolidation therapy with RIT versus ASCT in patients with FL in CR or PR after second or third line chemotherapy…
- Trial name
- NCT01827605
- Testing
- ZEVALIN, BEAM
- Where
- 38 sites in Italy
- Volunteers
- 159 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Follicular Lymphoma, Lymphoma
Epco, Zanu, Ritux for R/R FL or MZL
The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma (FL) or marginal zone…
- Conditions
- Follicular Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Relapsed Lymphoma
- Trial name
- NCT06563596
- Testing
- Zanubrutinib, Rituximab, Epcoritamab
- Where
- 3 sites in United States
- Volunteers
- 71 people
- Sponsor
- Reid Merryman, MD
Follicular Lymphoma, Diffuse Large B Cell Lymphoma
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
In this study, invesigators propose to analyze 150 DLBCL patients, 50 MCL patients, and 100 FL patients to determine the clinical utility of ctDNA- as well as circulating tumor cell (CTC)-based MRD assessment in CAR therapy…
- Conditions
- Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT05255354
- Testing
- ClonoSEQ
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Adaptive Biotechnologies
Diffuse Large B Cell Lymphoma, Follicular Lymphoma
A Trial of Radiotherapy and Durvalumab in DLBCL and FL
The primary objective for this study is to determine the safety profile of radiotherapy and durvalumab, a PD-L1 inhibitor. Primary endpoint: Toxicity, drug pharmacokinetics (PK), maximum tolerated dose (MTD) and recommended phase…
- Trial name
- RaDD (NCT03610061)
- Testing
- Durvalumab, Radiotherapy, Radiotherapy (cohort 6 only)
- Where
- 3 sites in Australia
- Volunteers
- 34 people
- Sponsor
- Austin Health
Follicular Lymphoma, Lymphoma, Large B-Cell, Diffuse
A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
This Phase Ib/II, open-label, multicenter, non-randomized, dose-escalation study will evaluate the safety, efficacy, and pharmacokinetics of obinutuzumab in combination with idasanutlin and venetoclax in participants with R/R FL…
- Trial name
- NCT03135262
- Testing
- Idasanutlin, Obinutuzumab, Venetoclax
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 29 people
- Sponsor
- Hoffmann-La Roche
Follicular Lymphoma, Lymphoma
Odronextamab in Low Tumor Volume Advanced FL
The purpose of this study is to evaluate the safety and effectiveness of treating previously untreated Follicular Lymphoma (FL) with odronextamab.
- Trial name
- NCT07128641
- Testing
- Odronextamab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Gottfried von Keudell, MD PhD
B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Long-term Follow up Local Registry Study of Kymriah in South Korea
This study is multicenter, primary data collection, non-interventional registry study to assess long-term safety, secondary malignancy risk, and effectiveness of tisagenlecleucel in patients with B-cell malignancies in a routine…
- Trial name
- NCT06785818
- Testing
- Tisagenlecleucel
- Where
- 18 sites in South Korea
- Volunteers
- 500 people
- Sponsor
- Novartis Pharmaceuticals
Inflammatory Bowel Diseases, Crohn Disease
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
Randomized, placebo-controlled dose-ranging study of 2'-FL in IBD, Crohn's Disease (CD) and ulcerative colitis (UC). The overarching hypothesis is that 2'-FL supplementation in IBD will be safe and well tolerated, while…
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
- Trial name
- PRIME (NCT03847467)
- Testing
- 2'-Fucosyllactose
- Where
- 3 sites in United States
- Volunteers
- 128 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study
This study will provide continuing availability to tazemetostat for people that have previously completed participation in a tazemetostat study, either with monotherapy (single drug treatment) or combination therapy.
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epithelioid Sarcoma (ES)
- Trial name
- TRuST (NCT02875548)
- Testing
- Tazemetostat
- Where
- 34 sites in United States, Australia and 5 more
- Volunteers
- 58 people
- Sponsor
- Epizyme, Inc.
Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma
Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma
This phase II trial tests how well tafasitamab and rituximab works for the treatment of newly diagnosed follicular lymphoma. Tafasitamab is a monoclonal antibody.
- Conditions
- Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
- Trial name
- NCT07731789
- Testing
- Rituximab, Tafasitamab, Biospecimen Collection
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Washington